Skip to content
value.today

Turing Pharmaceuticals AG

🇨🇭 Baar, Switzerland, SwitzerlandPharmaceuticalsFounded 2014
Total raised
$90 M
1 round on record
Latest round
$90 M
Jul 2015
First round on record
Jul 2015
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Turing Pharmaceuticals AG
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2015$90 MNo. 1$50 to $250 million

Turing Pharmaceuticals AG: Raise no. 1, Jul 2015

Investors in this round

43 investors had bought by the notice of Aug 19, 2015: 43 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$90 M (amount offered: indefinite)
Smallest investment taken
$25,000
What was sold
equity, options or other rights to buy securities, other: Offering Amount includes senior secured term loan
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Switzerland

People named in the notice

  • Martin Shkreli · Executive Officer, Director
  • Michael Harrison · Executive Officer
  • Alan Geller · Director
  • Ron Tilles · Director
  • Walter Blum · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Michael Harrison, Chief Financial Officer. Source: SEC Form D and 1 amendment, newest notice filed Aug 19, 2015. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Turing Pharmaceuticals AG chose not to state its revenue in its newest notice of a funding round (Aug 2015).

    SEC Form D · Aug 2015

  • The industry group it chose in its notices: Pharmaceuticals.

    SEC Form D · Aug 2015

That is all the official record says: Turing Pharmaceuticals AG has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Turing Pharmaceuticals AG is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 43 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Turing Pharmaceuticals AG
NameRoleNamed in
Martin ShkreliExecutive officerAug 2015
Michael HarrisonExecutive officerAug 2015
Howard DorfmanExecutive officerAug 2015
Alan GellerDirectorAug 2015
Martin ShkreliDirectorAug 2015
Ron TillesDirectorAug 2015
Walter BlumDirectorAug 2015